Wet AMD 4 Symposium

Related

• 

  A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD

  Vrinda S. Hershberger, MD, PhD

  On Demand Cases, Courses, and Papers

  2021

• 

  Anti-VEGF Injection Prior Authorization Impacts on Retina Practices

  Sabin Dang, MD

  Updates from the Field

  2022

• 

  Washington Update

  John T. Thompson, MD

  Updates from the Field

  2018